$KAST News - Kasten Inc. Completes Merger With Dakota Life Sciences

Follow Us on Facebook   Follow Us on Twitter   Follow Us on You Tube   Follow Us on Linked In   Subscribe To Our Feed

Financial News Media Featured News

Published - March 7, 2017
headline

$KAST News - Kasten Inc. Completes Merger With Dakota Life Sciences - (FinancialNewsMedia.com Wire)

headline
SILVER SPRINGS, Nevada, - (http://www.financialnewsmedia.com News Alert) - Kasten, Inc. (OTC: KAST) announced today that it has completed a merger with Thru Pharma LLC dba DAKOTA Life Sciences. Upon review of Dakota during the phases of the JV setup, the Board of Directors and Members of Kasten and Dakota determined, it was in the best interests of both entities and their stockholders to consummate the merger of Kasten with and into Dakota with Kasten as the surviving entity.

Dakota Life Sciences is engaged in developing innovative health products utilizing Site Specific Penetration Technology SSPT(TM) technologies. These products include but are not limited to Thin Nail(R) (OTC First Aid Nail Antifungal), Symphony(TM) OTC First Aid Antibiotic, ThinNail(R) RX Topical Antifungal, Symphony(TM) RX Topical Antibiotic, Reserve(TM) Rx Line of Topical Antibiotics and an R&D pipeline of wound care and dermatology products, as well as other valuable life sciences technologies. Read this and more news for Kasten at: http://financialnewsmedia.com/profiles/kast.html

Dakota Life Sciences is a leading anti-infectives private pharmaceutical company with award-winning products designed to provide the highest efficacy for global patients at high risk of suffering from dangerous microbial and fungal infections.

"Dakota Life Sciences is the solution to take Kasten to the next level. They have a driven experienced management team and the product line already in place to enhance shareholder value," stated Jose Delgado, CEO of Kasten, Inc.

"Dakota Life Sciences is very pleased to combine forces with Kasten," said the President of Dakota Life Sciences, Steven Keough. "Our joint focus is to introduce a range of high efficacy affordable prescription and OTC pharmaceutical products that are unique to the market."

CONTACT:
Kasten, Inc.
702-860-2407
pr@kastenbiopharma.com

SOURCE Kasten, Inc.

Disclaimer:
FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which is a third party publisher that disseminates electronic information through multiple online media channels. FNMG's intended purposes are to deliver market updates and news alerts issued from private and publicly trading companies as well as providing coverage and increased awareness for companies that issue press to the public via online newswires. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. Information in this release is derived from a variety of sources that may or may not include the referenced company's publicly disseminated information. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. While this information is believed to be reliable, such reliability cannot be guaranteed. FNMG disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. This release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. This release is not without bias, and is considered a conflict of interest if compensation has been received by FNMG for its dissemination. To comply with Section 17(b) of the Securities Act of 1933, FNMG shall always disclose any compensation it has received, or expects to receive in the future, for the dissemination of the information found herein on behalf of one or more of the companies mentioned in this release. For current services performed FNMG has been compensated one thousand nine hundred dollars for Kasten, Inc. coverage by a non-affiliated third party. FNMG HOLDS NO SHARES OF Kasten, Inc.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.
_________________________________________________
DISCLAIMER
 
© 2016 FinancialNewsMedia.com. All Rights Reserved. Created, Designed, Owned & Operated by FN Media Group, LLC.
Follow Us on Facebook   Follow Us on Twitter   Follow Us on You Tube   Follow Us on Linked In   Subscribe To Our Feed
 
FinancialNewsMedia.com (FNM) is a third party publisher and news disemmination solutions provider of multimedia platforms that enable officers & directors, corporate communicators, public relations and investor relations officers to leverage content to engage with all their key audiences. Any ideas and opinions presented in any FNM News Alerts, Video clips, Press Releases, RSS Feeds or Social Network Posts are for informational purposes only, and do not reflect the opinions of FNM or any of its affiliates, subsidiaries or partners. UNDER NO CIRCUMSTANCES SHOULD ANY CONTENT CONTAINED HEREIN BE INTERPRETED TO REPRESENT TRADING OR INVESTMENT ADVICE. All viewers agree that under no circumstances will FNM, its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information contained on this or any affiliated website. Read Full Disclaimer.